Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)

NCT05698199 · clinicaltrials.gov ↗
PHASE1
Phase
ACTIVE_NOT_RECRUITING
Status
10
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Immunomic Therapeutics, Inc.